We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) announced that the FDA has approved Jivi (BAY94-9027) for the routine prophylactic treatment of hemophilia A in previously-treated adults and adolescents 12 years of age or older, in the United States. The FDA also approved Jivi for on-demand treatment and perioperative management of bleeding in the same population.
Jivi is a long acting PEGylated recombinant human Factor VIII (rFVIII) replacement therapy. It replaces the reduced or missing FVIII in adults and adolescents aged 12 years or older suffering from hemophilia A.
The recommended initial prophylactic regimen for Jivi is twice weekly, with the scope to dose every five days and further individually adjust to less or more frequent dosing based on bleeding episodes.
Bayer submitted a Biologics License Application (BLA) for Jivi in August 2017, which was accepted by the FDA in November 2017.
The FDA approval was based on results from the phase II/III PROTECT VIII study. Bayer has also submitted marketing authorization applications for Jivi in the European Union and Japan.
Shares of Bayer have decreased 24.3% against with the industry’s growth of 5.1% year to date.
In July, Bayer also received approval for Kovaltry by the Chinese regulatory authorities for use in adults and children with hemophilia. Kovaltry is a full-length recombinant Factor VIII product. Kovaltry has been approved in many countries including the United States, Europe and Japan. Another FVIII treatment in Bayer’s portfolio is Kogenate FS.
Some better-ranked stocks in the biotech sector are Gilead Sciences Inc. (GILD - Free Report) , Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Celgene Corp. . While Gilead and Ligand sport a Zacks Rank #1 (Strong Buy), Celgene carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead’s earnings per share estimates have increased from $6.11 to $6.57 for 2018 and from $6.36 to $6.48 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.43%. The stock has rallied 6.5% so far this year.
Ligand’s earnings per share estimates have moved up from $4.93 to $5.64 for 2018 and from $5.39 to $5.59 for 2019 in the last 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 59.54%. Share price of the company has increased 88.1% year to date.
Celgene’s earnings per share estimates have increased from $8.52 to $8.76 for 2018 and from $10.18 to $10.65 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 2.38%.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market.
Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A
Bayer AG (BAYRY - Free Report) announced that the FDA has approved Jivi (BAY94-9027) for the routine prophylactic treatment of hemophilia A in previously-treated adults and adolescents 12 years of age or older, in the United States. The FDA also approved Jivi for on-demand treatment and perioperative management of bleeding in the same population.
Jivi is a long acting PEGylated recombinant human Factor VIII (rFVIII) replacement therapy. It replaces the reduced or missing FVIII in adults and adolescents aged 12 years or older suffering from hemophilia A.
The recommended initial prophylactic regimen for Jivi is twice weekly, with the scope to dose every five days and further individually adjust to less or more frequent dosing based on bleeding episodes.
Bayer submitted a Biologics License Application (BLA) for Jivi in August 2017, which was accepted by the FDA in November 2017.
The FDA approval was based on results from the phase II/III PROTECT VIII study. Bayer has also submitted marketing authorization applications for Jivi in the European Union and Japan.
Shares of Bayer have decreased 24.3% against with the industry’s growth of 5.1% year to date.
In July, Bayer also received approval for Kovaltry by the Chinese regulatory authorities for use in adults and children with hemophilia. Kovaltry is a full-length recombinant Factor VIII product. Kovaltry has been approved in many countries including the United States, Europe and Japan. Another FVIII treatment in Bayer’s portfolio is Kogenate FS.
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft Price | Bayer Aktiengesellschaft Quote
Zacks Rank & Stocks to Consider
Bayer has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Gilead Sciences Inc. (GILD - Free Report) , Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Celgene Corp. . While Gilead and Ligand sport a Zacks Rank #1 (Strong Buy), Celgene carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead’s earnings per share estimates have increased from $6.11 to $6.57 for 2018 and from $6.36 to $6.48 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.43%. The stock has rallied 6.5% so far this year.
Ligand’s earnings per share estimates have moved up from $4.93 to $5.64 for 2018 and from $5.39 to $5.59 for 2019 in the last 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 59.54%. Share price of the company has increased 88.1% year to date.
Celgene’s earnings per share estimates have increased from $8.52 to $8.76 for 2018 and from $10.18 to $10.65 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 2.38%.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market.
Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>